HOMA-IR, an independent predictor of advanced liver fibrosis in metabolic-dysfunction associated fatty liver disease: a cross-sectional study in Egyptian patients

Résumé

While metabolic dysfunction-associated fatty liver disease (MAFLD) includes the homeostatic model assessment for insulin resistance (HOMA-IR) as one of the criteria to define metabolic dysregulation, the newly proposed metabolic dysfunction-associated steatotic liver disease (MASLD) has removed this criterion. We investigated whether the HOMA-IR can serve as an independent predictive marker for significant fibrosis in subjects with MAFLD. This is a cross-sectional multicenter study. We enrolled a total of 364 patients diagnosed with MAFLD. We conducted a multiple logistic regression analysis to assess the relationship between HOMA-IR and advanced stages of liver fibrosis (F ≥ 2), as assessed by the FIB-4 score and liver stiffness measurement (LSM). Each unit increase in insulin resistance, as measured by HOMA-IR, was associated with a 16% higher likelihood of displaying significant fibrosis, as determined by a non-invasive scoring test, regardless of diabetes or BMI status. HOMA-IR was independently associated with significant fibrosis in non-diabetic (OR: 1.14, 95% CI: 1.07-1.21, P < 0.001) and diabetic (OR: 1.03, 95% CI: 1.00-1.06, P = 0.03) patients. Moreover, significant fibrosis in lean was independently linked to HOMA-IR (OR: 1.06, 95% CI: 1.01-1.12, P = 0.03) and non-lean (OR: 1.04, 95% CI: 1.02-1.07, P < 0.001) patients. Insulin resistance measured by HOMA-IR should be assessed in patients with MAFLD as a key factor of disease progression and incorporated into the disease diagnostic criteria.

Citer ce document

Accès au document

Texte intégral en lecture en ligne, réservé aux abonnés SPHAERO et aux membres de l'institution. Se connecter

Auteur(s)

Statistiques

Consultations : 1

Téléchargements : 0